The aim of the study is to evaluate the safety, improvement of clinical symptoms and laboratory parameters of convalescent immune plasma treatment in severe Covid-19 patients with ARDS.
The aim of the study is to evaluate the safety, improvement of clinical symptoms with hypoxemia, metabolic and laboratory parameters of patients with convalescent immune plasma treatment in severe Covid-19 patients followed up in critical care unit.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
60
One dose of 200 mL of convalescent ımmune plasma derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to standart critical care treatment.
Istanbul Bagcılar Training and Research Hospital
Istanbul, Turkey (Türkiye)
Plasma ferritin level
Acute phase reactant
Time frame: 7. day
Lymphocyte count
Infection markers
Time frame: 7. day
D-Dimer level
Hypercoagulability
Time frame: 7. day
C-Reactive protein level
Infection markers
Time frame: 7. day
Plasma procalcitonin level
Infection markers
Time frame: 7. day
Plasma fibrinogen level
Coagulopathy
Time frame: 7. day
Fractional Inspired Oxygen Level
Arterial oxygenation
Time frame: 7. day
Partial Oxygen Saturation level
Arterial oxygenation
Time frame: 7. day
Arterial Oxygen level
Arterial oxygenation
Time frame: 7. day
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.